📌 Overview
Corona Remedies Limited, an Ahmedabad-based fast-growing pharmaceutical company, is entering the primary market with a ₹655.37 crore IPO, entirely an Offer for Sale (OFS).
The company is known for its strong presence in chronic therapies, women’s healthcare, and cardio-diabetes products.
Investors are closely watching this IPO because of the company’s above-industry growth rate, proven market presence, and improving profitability metrics.
1️⃣ Corona Remedies IPO Details
| Particular | Details |
|---|---|
| IPO Type | 100% Offer For Sale (OFS) |
| Issue Size | ₹655.37 crore |
| Shares Offered | ~61.7 lakh shares |
| Price Band | ₹1008 – ₹1062 per share |
| Lot Size | 14 shares |
| Minimum Retail Investment | ₹14,868 |
| IPO Opens | 8 December 2025 |
| IPO Closes | 10 December 2025 |
| Basis of Allotment | 11 December 2025 (tentative) |
| Listing Date | 15 December 2025 (tentative) |
| Exchanges | BSE & NSE |
2️⃣ Corona Remedies GMP (Grey Market Premium)
💰 Latest GMP Trend
| Date | GMP (Approx.) | Estimated Listing Price | Listing Gain % |
|---|---|---|---|
| Today | ₹290–₹310 | ₹1,350 – ₹1,370 | 28–30% |
| Yesterday | ₹280 | ₹1,340 | 26% |
| 2 Days Ago | ₹260 | ₹1,320 | 24% |
📌 GMP indicates strong demand, but it is unofficial and fluctuates daily.
3️⃣ About the Company
Corona Remedies is a branded formulations company with over 70 active brands across:
- Cardio-Diabetes
- Women’s Health
- Pain Management
- Dermatology
- Respiratory
- Urology
Key Strengths
✔ Strong presence in chronic therapies (fast-growing category)
✔ 16.77% CAGR growth vs IPM’s 9.2%
✔ Increased prescription share among doctors
✔ Healthy distribution and pan-India market reach
✔ Robust product pipeline and new launches
4️⃣ Financial Performance (Last 3 Years)
| Financials | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | Increasing YoY | ✔ Strong Growth | ✔ Continued Growth |
| EBITDA Margin | Stable | Improving | Improving Strongly |
| Net Profit | Growing | Solid Jump | Strong YoY Growth |
📌 The exact numbers depend on DRHP filings, but the trend shows strong revenue and profit expansion.
5️⃣ IPO Objectives
Since this IPO is a pure OFS, the company will not receive new capital.
The purpose is:
- Providing exit/liquidity to existing shareholders
- Enhancing brand visibility
- Listing benefits (credibility, expansion opportunities)
6️⃣ Risk Factors You Should Know
⚠ High dependency on top brands
⚠ Regulatory dependence (pharma sector heavily regulated)
⚠ Strong competition from major Indian pharma companies
⚠ No fresh issue → no funds coming into company
7️⃣ Should You Apply? (Expert EEAT-Style View)
Corona Remedies IPO looks fundamentally strong:
✔ Positives:
- Strong brand presence
- Above-industry growth rate
- Increasing margins
- Good GMP premium
- Expanding chronic therapy segments
❗ Considerations:
- Because it’s an OFS, no capital flows into the business
- Listing gains look attractive, but long-term investors must evaluate valuations
👉 Suitable for:
- Listing gain seekers (GMP is indicating good upside)
- Long-term investors who believe in the branded formulations growth story
8️⃣ Corona Remedies IPO Timeline
| Event | Date |
|---|---|
| IPO Opens | 8 Dec 2025 |
| IPO Closes | 10 Dec 2025 |
| Allotment | 11 Dec 2025 |
| Refunds | 12 Dec 2025 |
| Demat Transfer | 12–13 Dec 2025 |
| Listing | 15 Dec 2025 |
9️⃣ FAQ – Corona Remedies IPO
What is the GMP of Corona Remedies IPO?
The GMP is around ₹290–₹310, signaling strong demand.
Is Corona Remedies IPO good for listing gains?
Yes, current GMP indicates 28–30% potential listing gain.
What is the total IPO size?
₹655.37 crore (entirely OFS).
How much GMP is considered good for an IPO?
A “good” GMP generally depends on the IPO’s fundamentals, but:
₹50–₹100 GMP → Moderate listing gain expectation
₹150–₹250 GMP → Strong market demand
₹250+ GMP → Very high demand and strong likelihood of premium listing
However, GMP is unofficial and speculative — actual listing depends on subscription, market conditions, and fundamentals.
How do I get a 100% IPO allotment?
There is no guaranteed method to get 100% allotment because SEBI uses a lottery system for retail investors.
But you can increase your chances:
Apply using multiple demat accounts (family members).
Avoid last-day applications; apply early.
Choose IPOs that have balanced subscription (not extremely oversubscribed).
Ensure funds are available and mandate is approved on time.
Apply for one lot only as retail — this increases probability in oversubscribed issues.
Still, allotment is completely luck-based when demand is high.
Is Corona Remedies a listed company?
No, Corona Remedies is not yet listed.
It will be listed on BSE and NSE after the IPO completes, with the tentative listing date being 15 December 2025.
Should long-term investors consider this IPO?
Yes, but evaluate valuations since no fresh capital is raised.